Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Clive S. Zent, Deborah A. Bowen, Michael J. Conte, Betsy R. LaPlant & Timothy G. Call. (2016) Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study. Leukemia & Lymphoma 57:7, pages 1585-1591.
Read now
Read now
Izaskun Ceberio, Sean M. Devlin, Craig Sauter, Juliet N. Barker, Hugo Castro-Malaspina, Sergio Giralt, Doris M. Ponce, Lauren Lechner, Molly A. Maloy, Jenna D. Goldberg & Miguel-Angel Perales. (2015) Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. Leukemia & Lymphoma 56:3, pages 663-670.
Read now
Read now
Matthew S. Davids & Jennifer R. Brown. (2012) Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leukemia & Lymphoma 53:12, pages 2362-2370.
Read now
Read now
S Galimberti & M Petrini. (2010) Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma. Cancer Management and Research 2, pages 181-189.
Read now
Read now
Rami Hayun, Eitan Okun, Alain Berrebi, Lev Shvidel, Lucette Bassous, Benjamin Sredni & Uri Nir. (2009) Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells. Leukemia & Lymphoma 50:4, pages 625-632.
Read now
Read now
Thomas Decker. (2008) Is mTOR inhibition a therapeutic option in chronic lymphocytic leukemia?. Leukemia & Lymphoma 49:12, pages 2235-2236.
Read now
Read now
Articles from other publishers (19)
Natasha Malik, Jodie Hay, Hassan N. B. Almuhanna, Karen M. Dunn, Jamie Lees, Jennifer Cassels, Jiatian Li, Rinako Nakagawa, Owen J. Sansom & Alison M. Michie. (2023) mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia. Leukemia 37:12, pages 2414-2425.
Crossref
Crossref
Rachel ThijssenJohanna ter BurgBrett GarrickGregor G. W. van BochoveJennifer R. BrownStacey M. FernandesMaría Solé RodríguezJean-Marie MichotMichael HallekBarbara EichhorstHans Christian ReinhardtJohanna BendellIngrid A. M. Derks, Roel J. W. van Kampen, Kristen HegeMarie José Kersten, Torsten TroweEllen H. FilvaroffEric Eldering & Arnon P. Kater. (2016) Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood 128:4, pages 574-583.
Crossref
Crossref
Austin Y. Shull, Satish K. Noonepalle, Farrukh T. Awan, Jimei Liu, Lirong Pei, Roni J. Bollag, Huda Salman, Zhiyong Ding & Huidong Shi. (2015) RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia. Oncotarget 6:16, pages 14632-14645.
Crossref
Crossref
Leigh A. Humphries, J. Claire Godbersen, Olga V. Danilova, Prabhjot Kaur, Brock C. Christensen & Alexey V. Danilov. (2013) Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia. British Journal of Haematology 163:5, pages 590-602.
Crossref
Crossref
Karolina Nemes, Anna Sebestyén, Ágnes Márk, Melinda Hajdu, István Kenessey, Tamás Sticz, Eszter Nagy, Gábor Barna, Zsófia Váradi, Gábor Kovács, László Kopper & Monika Csóka. (2013) Mammalian Target of Rapamycin (mTOR) Activity Dependent Phospho-Protein Expression in Childhood Acute Lymphoblastic Leukemia (ALL). PLoS ONE 8:4, pages e59335.
Crossref
Crossref
Carsten U. Niemann, Jade Jones & Adrian Wiestner. 2013. Advances in Chronic Lymphocytic Leukemia. Advances in Chronic Lymphocytic Leukemia
259
291
.
Jianguo Tao & Chih-Chi Andrew Hu. 2012. Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics. Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics
1
20
.
Kevin R. Kelly, Julie H. Rowe, Swaminathan Padmanabhan, Steffan T. Nawrocki & Jennifer S. Carew. (2011) Mammalian target of rapamycin as a target in hematological malignancies. Targeted Oncology 6:1, pages 53-61.
Crossref
Crossref
N Chapuis, J Tamburini, A S Green, L Willems, V Bardet, S Park, C Lacombe, P Mayeux & D Bouscary. (2010) Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 24:10, pages 1686-1699.
Crossref
Crossref
Clive S. Zent, Betsy R. LaPlant, Patrick B. Johnston, Timothy G. Call, Thomas M. Habermann, Ivana N. Micallef & Thomas E. Witzig. (2010) The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer, pages NA-NA.
Crossref
Crossref
M Plander, S Seegers, P Ugocsai, S Diermeier-Daucher, J Iványi, G Schmitz, F Hofstädter, S Schwarz, E Orsó, R Knüchel & G Brockhoff. (2009) Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia 23:11, pages 2118-2128.
Crossref
Crossref
David T. Teachey, Stephan A. Grupp & Valerie I. Brown. (2009) Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. British Journal of Haematology 145:5, pages 569-580.
Crossref
Crossref
Thomas Decker, Michael Sandherr, Katharina Goetze, Madlen Oelsner, Ingo Ringshausen & Christian Peschel. (2008) A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Annals of Hematology 88:3, pages 221-227.
Crossref
Crossref
G. D'Ythurbide, P. Coppo, A. Adem, P. Callard, J. Dantal, F. Chantrel, M. Godin, L. Braun-Parvez, B. Moulin, P. Moskovtchenko, N. Ouali, E. Rondeau & A. Hertig. (2008) Chronic Lymphocytic Leukemia: A Hazardous Condition Before Kidney Transplantation. American Journal of Transplantation 8:11, pages 2471-2475.
Crossref
Crossref
Valerie I. Brown, Alix E. Seif, Gregor S. D. Reid, David T. Teachey & Stephan A. Grupp. (2008) Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. Immunologic Research 42:1-3, pages 84-105.
Crossref
Crossref
Aaron E. Foster, Malcolm K. Brenner & Gianpietro Dotti. (2008) Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia. Best Practice & Research Clinical Haematology 21:3, pages 375-389.
Crossref
Crossref
Edwin P. Alyea, Shuli Li, Haesook T. Kim, Corey Cutler, Vincent Ho, Robert J. Soiffer & Joseph H. Antin. (2008) Sirolimus, Tacrolimus, and Low-Dose Methotrexate as Graft-versus-Host Disease Prophylaxis in Related and Unrelated Donor Reduced-Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 14:8, pages 920-926.
Crossref
Crossref
Isam A. Abdel-Karim & Francis J. Giles. (2008) Mammalian Target of Rapamycin as a Target in Hematological Malignancies. Current Problems in Cancer 32:4, pages 161-177.
Crossref
Crossref
Julio Pascual, Ioannis N. Boletis & Josep M. Campistol. (2006) Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplantation Reviews 20:1, pages 1-18.
Crossref
Crossref